Kangtai Bio | Briefing, News, Analysis, Research, Data

Kangtai Bio

Kangtai Bio a famous international pharmaceutical company

Kangtai Bio is one of the first high-tech enterprises in Shenzhen, mainly engaged in the development, production and sales of biological products. It has a team of vaccine industry professionals who have made important breakthroughs in the research and development of new vaccines. The production line is imported from Merck, a famous international pharmaceutical company, and its safety and efficacy have been guaranteed, and the products have covered 31 provinces, municipalities and autonomous regions.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Founded

Sept 8, 1992

HQ location

Guangdong, China

Legal name

Shenzhen Kangtai Biological Products Co., Ltd.

Website

http://www.biokangtai.com/

office@biokangtai.com

Employees

501-1000

All
News
Analysis
Research

Briefing Jan 30, 2023 10:44 AM · Healthcare

Levostar Completes Pre-A Financing Round to Further Invest in CGT

Briefing Jan 18, 2023 10:59 AM · Healthcare

BlissBio Nets Over CNY 100 Mn in Series B+

In-depth

Healthcare

Chinese Company Turned the Tables on Domestic Cell Culture Media Market

In this article, EqualOcean mainly introduce the history, competition, lead company, future trend in domestic cell culture media industry.

Feb 02, 2023 10:45 AM

Briefing Sep 21, 2022 10:38 AM · Healthcare

Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round

Briefing Sep 16, 2022 11:10 PM · Healthcare

NaviSeed Nets Tens of millions of CNY in Angel Round

Research

Healthcare

Digital Therapeutics - Revolution of the healthcare system

Nov 16, 2022 05:19 PM

Research

Healthcare

2022 China AI Health 30 Report

Nov 07, 2022 04:27 PM

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Technology, Healthcare, Financials

WIA2020 | 30 Tech Entrepreneurs in China

Apr 22, 2021 03:11 PM

Briefing Sep 13, 2022 05:30 PM · Healthcare

Nuwacell Nets Hundreds of Mns of CNY in Series A

Briefing Jun 27, 2022 06:44 PM · Technology | Healthcare

Zhongxin fluoromaterials: it is planned to acquire 51% equity of Jiangxi Exxon through equity transfer and cash capital increase

Briefing Jan 28, 2022 07:49 PM · Technology | Healthcare

Kangtai biology: the net profit in 2021 is expected to increase by 76.68% - 106.13% year-on-year

Briefing Jan 23, 2022 05:59 PM · Healthcare

Kangtai biology: CDE starts the on-site verification of the registration of freeze-dried human rabies vaccine (human diploid cells)

Healthcare

Real And Best Nets Over CNY 200 Mn in Series A+

Gene therapy company Real And Best accelerates to promote pipelines covering genetic disease, metabolism, and aging

Feb 02, 2023 11:53 AM

In-depth

Healthcare

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Jan 30, 2023 02:13 PM

Briefing Sep 17, 2021 02:24 PM · Technology | Consumer Staples

Before the festival, the market of "drinking and taking medicine" reappeared, and the food and beverage ETF (515170) rose 2.5%

Briefing Sep 17, 2021 12:03 PM · Technology | Healthcare

2021 China Internet development innovation and investment competition (Changsha) public welfare project and Beidou Innovation Application Challenge kicked off

Briefing Sep 05, 2021 05:52 PM · Healthcare | Financials

Anxin strategy: high prosperity configuration and low position trading

Healthcare

Biopharma Company IASO Bio Nets Nearly CNY 500 Mn in Series C1

The Chinese leading cell therapy company IASO Bio will soon launch its first commercialized CAR-T product

Jan 18, 2023 10:43 AM

Insight

Healthcare

Opportunities and Challenges Hidden in the CGT Industry in China

CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

Jan 17, 2023 05:48 PM

Briefing Aug 06, 2021 01:08 PM · Technology | Healthcare | Financials

Will Huawei's server business be packaged for sale? Huawei insiders: business is affected but will not give up

Briefing Jul 23, 2021 10:13 AM · Healthcare

Pharmaceutical and biological stocks fell sharply in early trading

Briefing Jul 19, 2021 05:45 PM · Technology | Healthcare | Financials

Samsung Xincai replied to the regulatory letter: there is no direct or indirect misappropriation of raised funds through entrusted loans

Briefing May 26, 2021 10:06 AM · Healthcare | Financials

Vaccine stocks weakened in early trading

EqualOcean Analysis